Clinical Trials Directory

Trials / Completed

CompletedNCT05635383

REBOUND PAIN AFTER PERIPHERAL NERVE BLOCKS

Investigation of the Frequency and Causes of Rebound Pain Phenomenon After Peripheral Nerve Blocks

Status
Completed
Phase
Study type
Observational
Enrollment
386 (actual)
Sponsor
Diskapi Yildirim Beyazit Education and Research Hospital · Other Government
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

In recent years, the use of regional anesthesia techniques as part of multimodal analgesia strategies to maximize pain control in patients has reduced opioid requirements and promoted early mobility and rehabilitation in the perioperative period. Regional anesthesia has benefits, mainly peripheral nerve blocks (PNB), muscle relaxation, and postoperative analgesia, thus allowing for control of postoperative pain and early discharge from the hospital. In addition, using PNB techniques provides: Hemodynamic stability. Reduced need for a post-anesthetic care unit (PACU). Reduced unplanned hospitalization for pain control. Less airway management. Reduced incidence of opioid-related adverse events. Greater patient satisfaction The main feature of rebound pain is that it is severe pain, within 8-24 hours after PNB. It usually remains severe for 2-6 hours, but the subsequent pain trajectory is consistent with the recovery process expected at surgical intervention. Therefore, rebound pain is temporary and different from persistent post-surgical pain (PPSP). Rebound pain often occurs at night. However, this is probably related to the 8 to 12-hour duration of most single-injection PNBs and the completion of most elective surgeries during daylight hours.

Detailed description

This study aims to reveal the rebound pain profile, determine the risk factors, and contribute to developing strategies that can prevent rebound pain.

Conditions

Interventions

TypeNameDescription
OTHERPERIPHERAL NERVE BLOCKObservation of rebound pain after peripheral nerve block application

Timeline

Start date
2022-08-01
Primary completion
2024-01-01
Completion
2024-03-12
First posted
2022-12-02
Last updated
2024-03-28

Locations

2 sites across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT05635383. Inclusion in this directory is not an endorsement.